http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html si-local-file:///var/storage/secattach/20260616/26654017.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html Tue, 16 Jun 2026 16:05:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html si-local-file:///var/storage/secattach/20260616/26654017.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html Tue, 16 Jun 2026 16:05:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html si-local-file:///var/storage/secattach/20260616/26654017.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+08++Filed+by%3A+Sharma+Mani/26654017.html Tue, 16 Jun 2026 16:05:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html si-local-file:///var/storage/secattach/20260615/26643989.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html Mon, 15 Jun 2026 06:52:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html si-local-file:///var/storage/secattach/20260615/26643989.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html Mon, 15 Jun 2026 06:52:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html si-local-file:///var/storage/secattach/20260615/26643989.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASTRAZENECA+PLC+++++++++++For%3A+Jun+15/26643989.html Mon, 15 Jun 2026 06:52:00 -0400 AZN AZN O.00436461 http://www.streetinsider.com/Corporate+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html <p>AstraZeneca's (NASDAQ: AZN) Alexion unit said the FDA has accepted and granted priority review for its supplemental biologics license application for Ultomiris (ravulizumab) to treat adults with immunoglobulin A nephropathy.</p><p>The FDA grants priority review to applications for medicines that could offer significant improvements over available treatment options through safety or efficacy improvements. The agency's action date is expected in the fourth quarter of 2026.</p><p>Immunoglobulin A nephropathy is a rare inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease. More than 217,000 people are diagnosed with the condition in the U.S.</p><p>The application is based http://www.streetinsider.com/Corporate+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html Mon, 15 Jun 2026 03:00:33 -0400 AZN http://www.streetinsider.com/FDA/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html <p>AstraZeneca's (NASDAQ: AZN) Alexion unit said the FDA has accepted and granted priority review for its supplemental biologics license application for Ultomiris (ravulizumab) to treat adults with immunoglobulin A nephropathy.</p><p>The FDA grants priority review to applications for medicines that could offer significant improvements over available treatment options through safety or efficacy improvements. The agency's action date is expected in the fourth quarter of 2026.</p><p>Immunoglobulin A nephropathy is a rare inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease. More than 217,000 people are diagnosed with the condition in the U.S.</p><p>The application is based http://www.streetinsider.com/FDA/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html Mon, 15 Jun 2026 03:00:33 -0400 AZN http://www.streetinsider.com/Hot+Corp.+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html <p>AstraZeneca's (NASDAQ: AZN) Alexion unit said the FDA has accepted and granted priority review for its supplemental biologics license application for Ultomiris (ravulizumab) to treat adults with immunoglobulin A nephropathy.</p><p>The FDA grants priority review to applications for medicines that could offer significant improvements over available treatment options through safety or efficacy improvements. The agency's action date is expected in the fourth quarter of 2026.</p><p>Immunoglobulin A nephropathy is a rare inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease. More than 217,000 people are diagnosed with the condition in the U.S.</p><p>The application is based http://www.streetinsider.com/Hot+Corp.+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html Mon, 15 Jun 2026 03:00:33 -0400 AZN http://www.streetinsider.com/Hot+FDA+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html <p>AstraZeneca's (NASDAQ: AZN) Alexion unit said the FDA has accepted and granted priority review for its supplemental biologics license application for Ultomiris (ravulizumab) to treat adults with immunoglobulin A nephropathy.</p><p>The FDA grants priority review to applications for medicines that could offer significant improvements over available treatment options through safety or efficacy improvements. The agency's action date is expected in the fourth quarter of 2026.</p><p>Immunoglobulin A nephropathy is a rare inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease. More than 217,000 people are diagnosed with the condition in the U.S.</p><p>The application is based http://www.streetinsider.com/Hot+FDA+News/AstraZeneca+unit+receives+FDA+priority+review+for+rare+kidney+disease+treatment/26643206.html Mon, 15 Jun 2026 03:00:33 -0400 AZN http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543 http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html <p class="bwalignc"> <b><i>Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%</i></b> </p><p class="bwalignc"> <b><i>First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis</i></b> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s TRUQAP® (capivasertib)<i> </i>in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US http://www.streetinsider.com/Press+Releases/TRUQAP%C2%AE+%28capivasertib%29+combination+approved+in+the+US+as+first+and+only+targeted+treatment+for+PTEN-deficient+metastatic+hormone-sensitive+prostate+cancer/26642461.html Fri, 12 Jun 2026 18:44:00 -0400 A.06822034 A.11583436 A.14055798 A.22847412 A.30719247 A.60001765 AZN AZN AZN O.00411018 O.00436461 O.00487744 O.00847036 O.03960636 O.20026344 O.20738543